Carregant...
Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate
About 20% of patients with a history of atherosclerotic cardiovascular disease will experience further cardiovascular events despite maximal pharmacological treatment with cardioprotective drugs. This highlights the presence of residual cardiovascular risk in a significant proportion of patients and...
Guardat en:
| Publicat a: | Drugs Context |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioExcel Publishing Ltd
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6239018/ https://ncbi.nlm.nih.gov/pubmed/30459819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212557 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|